Inogen (INGN) to Post Earnings on Thursday

Inogen (NASDAQ:INGN) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Inogen to post earnings of ($0.17) per share and revenue of $95.2330 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Inogen (NASDAQ:INGN) last issued its earnings results on Thursday, May 7th. The medical technology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). Inogen had a negative return on equity of 12.90% and a negative net margin of 7.08%.The company had revenue of $85.11 million for the quarter, compared to analysts’ expectations of $82.35 million. On average, analysts expect Inogen to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Inogen Stock Performance

Inogen stock opened at $6.43 on Thursday. The company has a 50 day moving average price of $6.46 and a 200-day moving average price of $6.38. Inogen has a fifty-two week low of $5.34 and a fifty-two week high of $9.13. The company has a market capitalization of $174.12 million, a PE ratio of -7.07 and a beta of 1.58.

Analyst Upgrades and Downgrades

INGN has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research note on Friday, May 8th. Freedom Capital raised Inogen to a “strong-buy” rating in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Inogen currently has an average rating of “Moderate Buy”.

Insider Activity at Inogen

In other Inogen news, EVP Boyer Jennifer M. Yi sold 10,938 shares of Inogen stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $6.60, for a total value of $72,190.80. Following the transaction, the executive vice president owned 5,039 shares in the company, valued at $33,257.40. The trade was a 68.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.50% of the company’s stock.

Institutional Trading of Inogen

A number of institutional investors have recently modified their holdings of the company. Corient Private Wealth LLC bought a new position in shares of Inogen during the 4th quarter worth approximately $84,000. Tudor Investment Corp ET AL boosted its position in shares of Inogen by 10.1% in the 4th quarter. Tudor Investment Corp ET AL now owns 151,602 shares of the medical technology company’s stock worth $1,019,000 after purchasing an additional 13,952 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new stake in Inogen in the fourth quarter worth about $145,000. Moore Capital Management LP grew its position in Inogen by 73.5% during the 4th quarter. Moore Capital Management LP now owns 200,005 shares of the medical technology company’s stock worth $1,344,000 after purchasing an additional 84,696 shares during the last quarter. Finally, Boothbay Fund Management LLC acquired a new position in shares of Inogen in the 4th quarter valued at $86,000. 89.94% of the stock is currently owned by institutional investors.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.